申请人:Novartis Vaccines and Diagnostics, Inc.
公开号:EP1767525A1
公开(公告)日:2007-03-28
Compounds having general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C=O, C=S, S=O, SO2, S, O, (CR6R7)n, C(=O)-(CR6R7)n, and C(=S)-(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (1a) and (1b). L is selected from the group consisting of N, O, S=O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (MC-4R) and therefore may have useful properties for controlling diseases related to MC-4R action in humans, such as obesity and type II diabetes.
提供了具有一般结构 I 的化合物。X 和 Y 独立选自由 CH2、N、NR9、C=O、C=S、S=O、SO2、S、O、(CR6R7)n、C(=O)-(CR6R7)n 和 C(=S)-(CR6R7)n(其中 n 为 1、2 或 3)组成的组。W 选自 (1a) 和 (1b) 所组成的组。L 选自由 N、O、S=O、SO2、C(O)、NC(O)、NC(S)、OC(O)、OC(S)、C(NR10)、C(NOR10) 和共价键组成的组。Z1、Z2 和 Z3 独立选自取代的碳和氮组成的组。式 I 的化合物是黑色素皮质素-4 受体(MC-4R)的激动剂,因此可能具有控制与 MC-4R 作用有关的人类疾病(如肥胖症和 II 型糖尿病)的有用特性。